← Eichor
Study identifier: NCT04629053 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia

Condition: Acute Febrile Illness  ·  Sponsor: University of Oxford

PhaseN/A
Planned participants7200
Who can joinAll sexes, 29 Days to no upper limit
Healthy volunteersNo

About this study

This prospective multi-site observational study aims to describe causes and clinical outcomes of acute febrile illness as well as host biomarkers in patients aged \>28 days residing in rural areas in Laos, Myanmar, Thailand, the Thai-Myanmar border region, and Bangladesh and presenting with acute febrile illnesses (≤ 14 days duration) to participating health facilities. This study is funded by the UK Wellcome Trust. The grant reference number is 215604/Z/19/Z

This description comes directly from the study's public registry record.

Talk to the study team

Yoel Lubell, Prof.  ·  +66-857201350  ·  yoel@tropmedres.ac

Rusheng Chew, Dr.  ·  chris@tropmedres.ac

Always discuss trial participation with your own doctor first.

Locations (4)

Building Resources Across Communities (BRAC)Dhaka, BangladeshNot Yet Recruiting
Laos-Oxford-Mahosot Wellcome Trust Research UnitVientiane, LaosRecruiting
Shoklo Malaria Research UnitMae Sot, Changwat Tak, ThailandRecruiting
Chiangrai Clinical Research Unit (CCRU)Chiang Rai, ThailandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04629053